ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

HBIO vs EYPT // 10Y YIELD & FRED MACRO BETA

Harvard Bioscience Inc. (NASDAQ) VS. EyePoint Inc. (NASDAQ) • 15-METRIC TALLY: HBIO 5 — EYPT 0
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (HBIO VS. EYPT) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC HBIO EYPT SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 57.70% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield 13.66% — — TIE /fcf-yield <GO>
Operating Margin -56.10% -60.00% +3.90 HBIO /operating-margins <GO>
Net Profit Margin -60.00% -60.00% 0.00 TIE /net-margins <GO>
Revenue Growth (YoY) -8.10% -27.50% +19.40 HBIO /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.20 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 5/9 1/9 +4.00 HBIO /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 68.8 15.7 +53.13 HBIO /rsi-technicals <GO>
10Y Yield & FRED Macro Beta ACTIVE — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $40.1M $32.8M $7.3M HBIO /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR HBIO REV EYPT REV HBIO GROSS % EYPT GROSS % HBIO FCF EYPT FCF
FY 2025 $86.5M $31.4M 57.7% — $5.5M -$243.4M
FY 2024 $94.1M $43.3M 58.2% — -$1.2M -$130.3M
FY 2023 $112.3M $46.0M — — $14.0M $1.9M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
HBIO // BETA —
EYPT // BETA —